Sarna's journey began with personal health challenges that inspired her to found nVision, which developed an FDA-cleared device for early ovarian cancer diagnosis. After selling nVision and spending time at Y Combinator, Sarna identified a significant opportunity in automating life sciences documentation. Collate, still in its early stages without a commercial product, aims to hire rapidly and build a strong company culture. With its substantial initial funding, Collate seeks to capitalize on the growing demand for AI-driven solutions in the healthcare sector.
Key takeaways:
- Surbhi Sarna, who previously sold her startup nVision Medical for $275 million, is launching a new startup called Collate to automate documentation in life sciences using AI.
- Collate has emerged from stealth with $30 million in seed funding, led by Redpoint, and is valued at over $100 million.
- The startup aims to sign on large life science customers and automate the creation of essential documents using generative AI tools.
- Sarna is leaving her role at Y Combinator to focus on Collate, teaming up with Nate Smith as cofounder and CTO to build the company.